| Signal transduction by tumor necrosis factor receptors L Cabal-Hierro, PS Lazo Cellular signalling 24 (6), 1297-1305, 2012 | 560 | 2012 |
| Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax J Montero, J Stephansky, T Cai, GK Griffin, L Cabal-Hierro, K Togami, ... Cancer discovery 7 (2), 156-164, 2017 | 199 | 2017 |
| TRAF-mediated modulation of NF-kB AND JNK activation by TNFR2 L Cabal-Hierro, M Rodríguez, N Artime, J Iglesias, L Ugarte, MA Prado, ... Cellular signalling 26 (12), 2658-2666, 2014 | 81 | 2014 |
| NF-κB signal triggering and termination by tumor necrosis factor receptor 2 M Rodríguez, L Cabal-Hierro, MT Carcedo, JM Iglesias, N Artime, ... Journal of Biological Chemistry 286 (26), 22814-22824, 2011 | 66 | 2011 |
| Trisomy of a Down syndrome critical region globally amplifies transcription via HMGN1 overexpression CT Mowery, JM Reyes, L Cabal-Hierro, KJ Higby, KL Karlin, JH Wang, ... Cell reports 25 (7), 1898-1911. e5, 2018 | 56 | 2018 |
| Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis K Togami, SS Chung, V Madan, CAG Booth, CM Kenyon, L Cabal-Hierro, ... Cancer discovery 12 (2), 522-541, 2022 | 53 | 2022 |
| Chromatin accessibility promotes hematopoietic and leukemia stem cell activity L Cabal-Hierro, P van Galen, MA Prado, KJ Higby, K Togami, CT Mowery, ... Nature communications 11 (1), 1406, 2020 | 47 | 2020 |
| A TRAF2 binding independent region of TNFR2 is responsibl for TRAF2 depletion and enhancement of cytotoxicity driven b TNFR1 L Cabal-Hierro, A Noelia, J Iglesias, L Ugarte-Gil, C Pedro, ... Oncotarget 5 (1), 224, 2014 | 32 | 2014 |
| Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents ODPJ Vasilevskaya IA, Selvakumaran M, Hierro LC, Goldstein SR, Winkler JD Clinical Cancer Research 21 (18), 4143-52, 2015 | 26 | 2015 |
| TNF signaling through RIP1 kinase enhances SN38-induced death in colon adenocarcinoma L Cabal-Hierro, PJ O'Dwyer Molecular Cancer Research 15 (4), 395-404, 2017 | 21 | 2017 |
| Microtubule interfering agents and KSP inhibitors induce the phosphorylation of the nuclear protein p54nrb, an event linked to G2/M arrest P Casado, MA Prado, P Zuazua-Villar, E Del Valle, N Artime, ... Journal of proteomics 71 (6), 592-600, 2009 | 13 | 2009 |
| Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov. 2017; 7: 156–164. doi: 10.1158/2159-8290 J Montero, J Stephansky, T Cai, GK Griffin, L Cabal-Hierro, K Togami, ... CD-16-0999.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 13 | |
| Proteomic analysis of annexin A2 phosphorylation induced by microtubule interfering agents and kinesin spindle protein inhibitors B Fernandez-Garcia, P Casado, MA Prado, LJ Ugarte-Gil, N Artime, ... Journal of Proteome Research 9 (9), 4649-4660, 2010 | 7 | 2010 |
| Phosphorylation of human eukaryotic elongation factor 1Bγ is regulated by paclitaxel MA Prado, P Casado, P Zuazua‐Villar, E del Valle, N Artime, ... Proteomics 7 (18), 3299-3304, 2007 | 5 | 2007 |
| Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Is Highly BCL-2 dependent and sensitive to venetoclax J Montero, J Stephansky, T Cai, GK Griffin, K Togami, L Cabal-Hierro, ... Blood 128 (22), 4045, 2016 | 2 | 2016 |
| Male-biased spliceosome mutations in blastic plasmacytoid dendritic cell neoplasm (BPDCN) impair pDC activation and apoptosis K Togami, SS Chung, V Madan, CM Kenyon, L Cabal-Hierro, J Taylor, ... Blood 136, 13-14, 2020 | 1 | 2020 |
| Nucleosome Binding Protein HMGN1 Promotes HSPC Competitive Advantage with Decreased Quiescence and Cooperates with AML Oncogenes to Block Differentiation and Increase Clonogenicity L Cabal-Hierro, K Togami, K Higby, AA Lane Blood 132, 2606, 2018 | | 2018 |
| NUCLEOSOME BINDING PROTEIN HMGN1 BLOCKS MYELOIDDIFFERENTIATION AND PROMOTES CLONAL DOMINANCE VIA ABERRANT HISTONE ACETYLATION L Cabal-Hierro, P Van Galen, M Prado, K Togami, C Mowery, K Higby, ... HAEMATOLOGICA 102, 153-154, 2017 | | 2017 |
| Potentiation of oxaliplatin in colon cancer by JNK inhibition I Vasilevskaya, M Selvakumaran, L Cabal-Hierro, P O’Dwyer European Journal of Cancer 50, 154-155, 2014 | | 2014 |
| Inhibition of JNK signaling sensitizes hypoxic colon cancer cells to DNA-damaging agents IA Vasilevskaya, M Selvakumaran, L Cabal-Hierro, PJ O'Dwyer Cancer Research 74 (19_Supplement), 488-488, 2014 | | 2014 |
Miguel A. PradoPostdoctoral Fellow, Harvard Medical SchoolVerified email at hms.harvard.edu
